EMA recommends Baxalta cancer drug; U.K.'s NHS speeds new cancer treatments to patients;

@FiercePharma: Price controls loom for generic drugs in India next year. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Report | Follow @EricPFierce

> The EMA has recommended approval of Baxalta's ($BXLT) Oncaspar; Baxter ($BAX) bought the cancer drug from Italy's Sigma-Tau Finanziaria for $900 million ahead of spinning Baxalta off this summer. Release

> South Africa's Ascendis Health has bought a competitor for $25 million. Story

> The EMA has recommended approval of a new treatment for narcolepsy. Release

> The U.K.'s National Health System is trying to speed the process of getting new cancer treatments to patients. Report

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: St. Jude earns FDA approval for recharge-free spinal cord stimulation system. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Bard to buy Liberator for $181M to improve access to home care market. Article

> Cancer diagnostics company closes up shop after 6-year FTC investigation. More

> Philips launches smartphone plug-in ultrasound handheld with app in U.S. Story

Biotech News

@FierceBiotech: TEDMED 2015: A brief history of CRISPR and what's next. Article | Follow @FierceBiotech

@JohnCFierce: To me, the FDA review of drisa reads like a letter to DMD parents. You don't want this drug. Please don't be angry.  | Follow @JohnCFierce

@DamianFierce: "Did you name me after the mayor of New York, dad?" "Yes, Kristaps, but he was just a basketball player then." | Follow @DamianFierce

> FDA takes a dim view of BioMarin's DMD drug, citing 'contradictory' data. Story

> Samsung and Biogen verge on EU approval with an Enbrel biosimilar. Report

> AstraZeneca, Sanofi swap 210,000 compounds in no-cash deal. Article

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.